(Q36832098)

16 August 2017

1 reference

title

Anti-idiotype antibodies in cancer treatment (English)

1 reference

16 August 2017

1 reference

A López-Díaz de Cerio

1

1 reference

16 August 2017

N Zabalegui

2

1 reference

16 August 2017

M Rodríguez-Calvillo

3

1 reference

16 August 2017

S Inogés

4

1 reference

16 August 2017

M Bendandi

5

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 May 2007

1 reference

16 August 2017

1 reference

16 August 2017

volume

26

1 reference

16 August 2017

issue

25

1 reference

16 August 2017

page(s)

3594-3602

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.onc.1210371

16 August 2017

exact match

0 references

cites work

Phenotypic and functional changes of tumour cells from patients treated with monoclonal anti-idiotypic antibodies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

Role of anti-idiotype vaccines in the modern treatment of human follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

The role of idiotype vaccines in the treatment of human B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

Anti-idiotypic DNA vaccines for lymphoma immunotherapy require the presence of both variable region genes for tumor protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

Cloning of idiotype immunoglobulin genes in B cell lymphomas by anchored PCR and production of individual recombinant idiotype vaccines in Escherichia coli.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

Anti-idiotype antibody vaccine therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

Structural basis of antigen mimicry in a clinically relevant melanoma antigen system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

Generation of anti-idiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

Cellular and humoral immune response to N-Glycolyl-GM3 elicited by prolonged immunotherapy with an anti-idiotypic vaccine in high-risk and metastatic breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphomas: a focus on FavId.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

Antibody-based vaccines for the treatment of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

Anti-tumor immunity induced by an anti-idiotype antibody mimicking human Her-2/neu

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

Vaccination with Ep-CAM protein or anti-idiotypic antibody induces Th1-biased response against MHC class I- and II-restricted Ep-CAM epitopes in colorectal carcinoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

Fine specificity of high molecular weight-melanoma-associated antigen-specific cytotoxic T lymphocytes elicited by anti-idiotypic monoclonal antibodies in patients with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

Idiotypic DNA vaccines against B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

A genetic approach to idiotypic vaccination for B cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

Humoral immune response and immunoglobulin G Fc receptor genotype are associated with better clinical outcome following idiotype vaccination in follicular lymphoma patients regardless of their response to induction chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

Immunotherapy with monoclonal anti-idiotypic antibodies: tumour reduction and lymphokine production

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

7 January 2021

Murine monoclonal anti-idiotypic antibody as a surrogate antigen for human Her-2/neu

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

7 January 2021

Clinical benefit of idiotype vaccines: too many trials for a clever demonstration?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

7 January 2021

Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

7 January 2021

Anti-idiotypic antibody and recombinant antigen vaccines in colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

7 January 2021

Anti-idiotypic antibody (ab2) vaccines: coupling of Ab2 BR3E4 to KLH increases humoral and/or cellular immune responses in animals and colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

7 January 2021

Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

7 January 2021

Immune responses in breast cancer patients immunized with an anti-idiotype antibody mimicking NeuGc-containing gangliosides

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

7 January 2021

Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

7 January 2021

A pilot study of idiotypic vaccination for follicular B-cell lymphoma using a genetic approach. CRC NO: 92/33. Protocol NO: PH1/027.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

7 January 2021

Modulation of cancer patients' immune responses by administration of anti-idiotypic antibodies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

7 January 2021

Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

7 January 2021

DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

7 January 2021

Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

7 January 2021

Idiotype vaccination in follicular lymphoma: knocking on the doorway to cure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

7 January 2021

Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

7 January 2021

Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype Antibody

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

7 January 2021

Phase III randomized trial of patient-specific vaccination for previously untreated patients with follicular lymphoma in first complete remission: protocol summary and interim report

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

7 January 2021

Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

7 January 2021

The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

7 January 2021

Spontaneous alteration of idiotype in a monoclonal B-cell lymphoma. Escape from detection by anti-idiotype

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

7 January 2021

Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

7 January 2021

Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

7 January 2021

Interim analysis of the use of the anti-idiotype breast cancer vaccine 11D10 (TriAb) in conjunction with autologous stem cell transplantation in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

7 January 2021

Use of the anti-idiotype antibody vaccine TriAb after autologous stem cell transplantation in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

7 January 2021

CpG oligonucleotides enhance the tumor antigen-specific immune response of an anti-idiotype antibody-based vaccine strategy in CEA transgenic mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

7 January 2021

Immunologic response to the dual murine anti-Id vaccine Melimmune-1 and Melimmune-2 in patients with high-risk melanoma without evidence of systemic disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

7 January 2021

Plant viral genes in DNA idiotypic vaccines activate linked CD4+ T-cell mediated immunity against B-cell malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

7 January 2021

Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

7 January 2021

A neoadjuvant/adjuvant randomized trial of colorectal cancer patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

7 January 2021

DNA fusion vaccines against B-cell tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210371

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1210371

1 reference

16 August 2017

1 reference